T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin

Bauer, Corinne; Pari, Ashik Ahmed Abdul; Umansky, Viktor; Utikal, Jochen; Boukamp, Petra; Augustin, Hellmut G.; Goerdt, Sergij; Géraud, Cyrill; Felcht, Moritz

doi:10.1007/s00262-018-2171-7

Cited by 15 publications

(18 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumors with a higher tumor mutational burden are known to be more responsive to immune checkpoint inhibitors [119][120][121]. In addition, the higher risk of immunocompromised patients developing CSCC indicates the importance of the immune system in this tumor [122,123]. For these reasons, clinical trials with these drugs for the treatment of CSCC were designed.…”

Section: Immunotherapy In Csccmentioning

confidence: 99%

Cutaneous Squamous Cell Carcinoma: From Biology to Therapy

Corchado-Cobos

García-Sancha

González-Sarmiento

et al. 2020

IJMS

121

111

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors. Another purpose of this review is to explore the landscape of drugs that may induce or contribute to the development of CSCC. Beginning with the pathogenetic basis of these drug-induced CSCCs, we move on to consider potential therapeutic opportunities for overcoming this adverse effect.

show abstract

Section: Immunotherapy In Csccmentioning

confidence: 99%

Cutaneous Squamous Cell Carcinoma: From Biology to Therapy

Corchado-Cobos

García-Sancha

González-Sarmiento

et al. 2020

IJMS

121

111

View full text Add to dashboard Cite

show abstract

“…Management of advanced cutaneous SCC has not been standardized; however, since the advent of immune checkpoint therapy, studies have evaluated the role of tumor-infiltrating lymphocytes35,36 and programmed death-ligand 1 (PD-L1) expression in tumor cells in cutaneous SCC37,38 and have established the efficacy of programmed death 1 (PD1) blockade in the management of advanced cutaneous SCC 39,40. To explore whether use of PD1/PD-L1-based immunotherapy might also be feasible in conjunctival SCC, we evaluated, in a series of 31 conjunctival SCCs, the expression of PD-L1 within tumor cells; the composition and density of tumor-associated immune infiltrates; relationships between PD-L1 expression, immune infiltrates, and clinicopathologic features, including HPV status; and relationships between various patient and disease features and prognosis.…”

mentioning

confidence: 99%

PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma

Nagarajan

El-Hadad

Gruschkus

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. Conjunctival squamous cell carcinoma (SCC), a type of ocular surface neoplasia, is primarily treated by surgical resection and topical immuno-or chemotherapy. Metastatic disease may be treated with systemic chemo-or immunotherapy, albeit with variable response. The purpose of this study was to determine whether immune checkpoint blockade might be considered in the management of conjunctival SCC. METHODS. In this retrospective study, we evaluated tumor programmed death-ligand 1 (PD-L1) expression, high-risk human papillomavirus (HPV) status, and immunohistochemical expression of cluster of differentiation 3 (CD3), cluster of differentiation 8 (CD8), and programmed death 1 (PD1) in tumor-associated immune infiltrate in a series of 31 conjunctival SCCs. RESULTS. PD-L1 expression in ‡1% of tumor cells was noted in 14 conjunctival SCCs (47%) and was more prevalent in invasive than in situ SCC and among tumors with higher American Joint Committee on Cancer (AJCC) T category (‡T3 versus T2). The density of CD3-positive T cells was higher in primary than recurrent tumors and higher in invasive than in situ tumors. Density of CD3-positive and CD8-positive T cells was higher in higher AJCC stage tumors. Density of CD8-positive T cells was higher in HPV-positive than HPV-negative tumors. PD-L1 expression correlated with a higher density of CD3-, CD8-, and PD1-positive cells in the tumor-associated immune infiltrate but not with HPV status. CONCLUSIONS. Our findings demonstrate that PD-L1 is expressed in almost half of conjunctival SCCs. The density of tumor-associated immune cells correlated with invasive SCC, stage, and HPV status in conjunctival SCC. Our findings support further studies to establish the potential application of immune checkpoint blockade in the management of conjunctival SCC.

show abstract

“…The inflammatory cells in KA are usually CD3+ and CD4+ TILs, with a small number of CD3+ and CD8+ TILs, which differs from the TIL profile of KCM. In addition, 30% of the KCM cases that spontaneously regressed were positive for PD‐L1 (Bauer et al, ). The present case was PD‐L1‐negative and did not spontaneously regress.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of oral retinoids for keratoacanthoma centrifugum marginatum

Mizuta

Takahashi

Mori

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Keratoacanthoma centrifugum marginatum (KCM) is a rare variant of keratoacanthoma. This condition is difficult to diagnose because of its large size and expansive nature and may be diagnosed as a malignant tumor. There are various treatments such as surgery and oral retinoids; however, limited studies have verified their effectiveness. Here, we report a case of KCM on the anterior chest of a 50‐year‐old woman and evaluate the efficacy of oral retinoids. In this case, oral retinoids were highly effective for KCM treatment. A total of 55 cases of KCM, including 54 previously reported cases, were reviewed, and their clinical characteristics and treatment were examined. In this report, 14 of 16 patients were effectively treated with oral retinoids, resulting in a treatment rate of 87.5%. Furthermore, even low‐to‐medium doses were sufficient for treatment and prevention. KCM can be misdiagnosed as a malignant disease based on its clinical features. Due to its large size and expansive nature, a wide excision may be performed; however, because oral retinoids have a very high response rate, an accurate diagnosis will help avoid an unnecessary wide excision.

show abstract

T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin

Abstract: Tumor-associated T-lymphocyte infiltrates showed significant differences between AK, KA and invasive cSCC. PD-L1 expression correlated with invasion of T-cell infiltrates in invasive cSCC.

Cited by 15 publications

References 54 publications

Cutaneous Squamous Cell Carcinoma: From Biology to Therapy

Cutaneous Squamous Cell Carcinoma: From Biology to Therapy

PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma

Efficacy of oral retinoids for keratoacanthoma centrifugum marginatum

Contact Info

Product

Resources

About